158 related articles for article (PubMed ID: 20464886)
1. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
[TBL] [Abstract][Full Text] [Related]
2. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.
Saif MW; Peccerillo J; Potter V
Cancer Chemother Pharmacol; 2009 May; 63(6):1017-22. PubMed ID: 18781300
[TBL] [Abstract][Full Text] [Related]
3. [Incidence of infusion reactions induced by cetuximab chemotherapy].
Maeda T; Tatematsu M; Muro K
Gan To Kagaku Ryoho; 2011 Jun; 38(6):963-6. PubMed ID: 21677487
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors.
Hopps S; Medina P; Pant S; Webb R; Moorman M; Borders E
J Oncol Pharm Pract; 2013 Sep; 19(3):222-7. PubMed ID: 23135806
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
6. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
[TBL] [Abstract][Full Text] [Related]
7. Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center.
Hansen NL; Chandiramani DV; Morse MA; Wei D; Hedrick NE; Hansen RA
J Oncol Pharm Pract; 2011 Jun; 17(2):125-30. PubMed ID: 20147576
[TBL] [Abstract][Full Text] [Related]
8. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.
O'Neil BH; Allen R; Spigel DR; Stinchcombe TE; Moore DT; Berlin JD; Goldberg RM
J Clin Oncol; 2007 Aug; 25(24):3644-8. PubMed ID: 17704414
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab for the treatment of colorectal cancer.
Jonker DJ; O'Callaghan CJ; Karapetis CS; Zalcberg JR; Tu D; Au HJ; Berry SR; Krahn M; Price T; Simes RJ; Tebbutt NC; van Hazel G; Wierzbicki R; Langer C; Moore MJ
N Engl J Med; 2007 Nov; 357(20):2040-8. PubMed ID: 18003960
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab infusion reactions: French pharmacovigilance database analysis.
Grandvuillemin A; Disson-Dautriche A; Miremont-Salamé G; Fourrier-Reglat A; Sgro C;
J Oncol Pharm Pract; 2013 Jun; 19(2):130-7. PubMed ID: 23154574
[TBL] [Abstract][Full Text] [Related]
11. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.
Heun J; Holen K
Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202
[TBL] [Abstract][Full Text] [Related]
12. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
Chung CH
Oncologist; 2008 Jun; 13(6):725-32. PubMed ID: 18586928
[TBL] [Abstract][Full Text] [Related]
13. Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT.
Studer G; Brown M; Salgueiro EB; Schmückle H; Romancuk N; Winkler G; Lee SJ; Sträuli A; Kissling B; Dummer R; Glanzmann C
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):110-7. PubMed ID: 20732757
[TBL] [Abstract][Full Text] [Related]
14. Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital.
Keating K; Walko C; Stephenson B; O'Neil BH; Weiss J
J Oncol Pharm Pract; 2014 Dec; 20(6):409-16. PubMed ID: 24243920
[TBL] [Abstract][Full Text] [Related]
15. Management and preparedness for infusion and hypersensitivity reactions.
Lenz HJ
Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
[TBL] [Abstract][Full Text] [Related]
16. Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer: results of a nationwide, multicenter, prospective registry study of 2126 patients in Japan.
Yamaguchi K; Watanabe T; Satoh T; Ishiguro M; Izawa M; Inoshiri S; Sugihara K; Sakata Y
Jpn J Clin Oncol; 2014 Jun; 44(6):541-6. PubMed ID: 24771864
[TBL] [Abstract][Full Text] [Related]
17. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).
Sastre J; Aranda E; Grávalos C; Massutí B; Varella-Garcia M; Rivera F; Soler G; Carrato A; Manzano JL; Díaz-Rubio E; Hidalgo M
Crit Rev Oncol Hematol; 2011 Jan; 77(1):78-84. PubMed ID: 20042346
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer.
Cao Y; Liao C; Tan A; Liu L; Gao F
Chemotherapy; 2010; 56(6):459-65. PubMed ID: 21088398
[TBL] [Abstract][Full Text] [Related]
19. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
20. Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports.
Nielsen DL; Pfeiffer P; Jensen BV
Acta Oncol; 2006; 45(8):1137-8. PubMed ID: 17118853
[No Abstract] [Full Text] [Related]
[Next] [New Search]
